We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
-12.02%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$760M
AUM Growth
+$89.2M
Cap. Flow
+$192M
Cap. Flow %
25.21%
Top 10 Hldgs %
39.48%
Holding
222
New
36
Increased
135
Reduced
20
Closed
26

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$9.39M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$8.96M
3
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$7.48M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.93M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$5.63M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$10.1M
2
BCYC
Bicycle Therapeutics
BCYC
+$6.27M
3
BIIB icon
Biogen
BIIB
+$6.18M
4
GOSS icon
Gossamer Bio
GOSS
+$3.78M
5
IBB icon
iShares Biotechnology ETF
IBB
+$3.67M

Sector Composition

Rank Sector Weight
1 Healthcare 42.6%
2 Consumer Staples 0.27%
3 Technology 0.24%
4 Financials 0.1%
5 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
201
BridgeBio Pharma
BBIO
$15.7B
– –
-1,500
Closed -$25K
BBIO icon
202
PUT
BridgeBio Pharma
BBIO
$15.7B
– –
-909,700
Closed -$15.2M
FOLD
203
DELISTED
Amicus Therapeutics
FOLD
– –
-164,174
Closed -$1.9M
IBB icon
204
iShares Biotechnology ETF
IBB
$9.34B
– –
-24,022
Closed -$3.67M
IOVA icon
205
Iovance Biotherapeutics
IOVA
$1.82B
– –
-172,521
Closed -$3.29M
IOVA icon
206
PUT
Iovance Biotherapeutics
IOVA
$1.82B
– –
-196,000
Closed -$3.74M
MDGL icon
207
Madrigal Pharmaceuticals
MDGL
$10.8B
– –
-23,700
Closed -$2.01M
RCUS icon
208
PUT
Arcus Biosciences
RCUS
$3.55B
– –
-124,600
Closed -$5.04M
RFL icon
209
Rafael Holdings
RFL
$101M
– –
-73,530
Closed -$370K
RFL icon
210
PUT
Rafael Holdings
RFL
$101M
– –
-101,400
Closed -$510K
SRPT icon
211
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-399,400
Closed -$36M
TGTX icon
212
PUT
TG Therapeutics
TGTX
$7.96B
– –
-98,600
Closed -$1.87M
XBI icon
213
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
– –
-542,400
Closed -$60.7M
DCPH
214
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-29,800
Closed -$291K
DCPH
215
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-800
Closed -$8K
MRTX
216
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-1,300
Closed -$191K
ICPT
217
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-1,100
Closed -$18K
FLACU
218
DELISTED
Frazier Lifesciences Acquisition Corporation Unit
FLACU
– –
-941
Closed -$9K
ARNA
219
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-22,300
Closed -$2.07M
ARNA
220
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-2,161
Closed -$200K
ODT
221
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-1,340,631
Closed -$1.81M
ZGNX
222
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-590,400
Closed -$9.59M
5 6 7 8
9

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Ikarian Capital held 222 positions worth $760M, up 13% from $671M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital deployed $192M of net new capital in Q1 2022, opening 36 new positions and adding to 135 existing holdings. Its largest new stake was Sage Therapeutics: 249,907 shares worth $8.27M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 51% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $10.1M trimmed.

  • Ikarian Capital's largest Q1 2022 buy was Sage Therapeutics: 249,907 shares worth $8.27M.
  • Ikarian Capital added most to BELLUS Health Inc. in Q1 2022, an estimated $5.56M increase.
  • Ikarian Capital's biggest Q1 2022 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $10.1M.
  • Ikarian Capital fully exited iShares Biotechnology ETF in Q1 2022, selling an estimated $3.67M.
  • Ikarian Capital's ten largest holdings make up 39% of its $760M portfolio in Q1 2022.
  • Ikarian Capital opened 36 new positions and closed 26 in Q1 2022.
  • Ikarian Capital's portfolio value rose 13% quarter-over-quarter to $760M.

Based on Ikarian Capital's 13F filing for Q1 2022, filed 13 May 2022.